Lubiprostone

Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

Amitiza in Constipation Associated With PD (Parkinson's Disease)

Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Lubiprostone in Children With Functional Constipation

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Lubiprostone for Children With Constipation

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Lubiprostone for Chronic Idiopathic Constipation Treatment